Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.

Manouk K BosS W LamG MottaJ C A HelmijrC M BeaufortE de JongeJ W M MartensE BovenM P H M JansenA JagerS Sleijfer

Published in: Breast cancer research and treatment (2023)

Presence of ESR1 mutations in baseline ctDNA might not be associated with inferior PFS and OS in advanced breast cancer patients treated with paclitaxel/bevacizumab.

Keyphrases

estrogen receptor
metastatic colorectal cancer
chemotherapy induced
young adults
breast cancer cells
circulating tumor cells
childhood cancer